Tattoo complications in treated and non-treated psoriatic patients.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
13
02
2019
accepted:
04
09
2019
pubmed:
1
10
2019
medline:
30
1
2021
entrez:
1
10
2019
Statut:
ppublish
Résumé
Tattooing is a widespread phenomenon, with an estimated prevalence of 10-30% in Western populations. For psoriasis patients, current recommendations are to avoid having a tattoo if the disease is active and they are receiving immunosuppressive treatments. Although scientific data supporting these recommendations are lacking, dermatologists are often reluctant to advocate tattooing in psoriasis patients. We aimed to evaluate the frequency of tattoo complications in patients with psoriasis and determine whether the occurrence of complications was associated with psoriasis status and treatments received at the time of tattooing. We performed a multicentre cross-sectional study. Adults with psoriasis were consecutively included and classified as tattooed or non-tattooed. Prevalence of complications associated with tattoos was then evaluated according to psoriasis onset and treatments. The study was divided into three parts, in which data were collected through a series of questionnaires filled in by the dermatologist. Complications included pruritus, oedema, allergic reaction/eczema, infection/superinfection, granuloma, lichenification, photosensitivity, Koebner phenomenon and psoriasis flare after tattooing. Diagnosis of complications was made retrospectively. We included 2053 psoriatic patients, 20.2% had 894 tattoos. Amongst non-tattooed patients, 15.4% had wished to be tattooed, with psoriasis being stated as a reason for not having a tattoo by 44.0% and 5.7% indicating that they planned to have a tattoo in the future. Local complications, such as oedema, pruritus, allergy and Koebner phenomenon, were reported in tattoos in 6.6%, most frequently in patients with psoriasis requiring treatment at the time of tattooing (P < 0.0001). No severe complications were reported. The rate of tattoo complications in psoriasis patients was low. Although the risk of complications was highest amongst patients with psoriasis requiring treatment at the time of tattooing, all the complications observed were benign. These results can be helpful for practitioners to give objective information to patients.
Sections du résumé
BACKGROUND
BACKGROUND
Tattooing is a widespread phenomenon, with an estimated prevalence of 10-30% in Western populations. For psoriasis patients, current recommendations are to avoid having a tattoo if the disease is active and they are receiving immunosuppressive treatments. Although scientific data supporting these recommendations are lacking, dermatologists are often reluctant to advocate tattooing in psoriasis patients.
OBJECTIVE
OBJECTIVE
We aimed to evaluate the frequency of tattoo complications in patients with psoriasis and determine whether the occurrence of complications was associated with psoriasis status and treatments received at the time of tattooing.
METHODS
METHODS
We performed a multicentre cross-sectional study. Adults with psoriasis were consecutively included and classified as tattooed or non-tattooed. Prevalence of complications associated with tattoos was then evaluated according to psoriasis onset and treatments. The study was divided into three parts, in which data were collected through a series of questionnaires filled in by the dermatologist. Complications included pruritus, oedema, allergic reaction/eczema, infection/superinfection, granuloma, lichenification, photosensitivity, Koebner phenomenon and psoriasis flare after tattooing. Diagnosis of complications was made retrospectively.
RESULTS
RESULTS
We included 2053 psoriatic patients, 20.2% had 894 tattoos. Amongst non-tattooed patients, 15.4% had wished to be tattooed, with psoriasis being stated as a reason for not having a tattoo by 44.0% and 5.7% indicating that they planned to have a tattoo in the future. Local complications, such as oedema, pruritus, allergy and Koebner phenomenon, were reported in tattoos in 6.6%, most frequently in patients with psoriasis requiring treatment at the time of tattooing (P < 0.0001). No severe complications were reported.
CONCLUSIONS
CONCLUSIONS
The rate of tattoo complications in psoriasis patients was low. Although the risk of complications was highest amongst patients with psoriasis requiring treatment at the time of tattooing, all the complications observed were benign. These results can be helpful for practitioners to give objective information to patients.
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
888-896Informations de copyright
© 2019 European Academy of Dermatology and Venereology.
Références
Kluger N. Epidemiology of tattoos in industrialized countries. Curr Probl Dermatol 2015; 48: 6-20.
The Harris poll. Tattoo takeover: three in ten Americans have tattoos, and most don't stop at just one. URL https://theharrispoll.com/tattoos-can-take-any-number-of-forms-from-animals-to-quotes-to-cryptic-symbols-and-appear-in-all-sorts-of-spots-on-our-bodies-some-visible-in-everyday-life-others-not-so-much-but-one-thi/. (last accessed: 15 January 2019).
Kluger N, Misery L, Seité S, Taieb C. Tattooing: A national survey in the general population of France. J Am Acad Dermatol 2018; 81: 607-610.
Serup J, Sepehri M, Hutton Carlsen K. Classification of tattoo complications in a hospital material of 493 adverse events. Dermatology 2016; 232: 668-678.
Kazandjieva J, Tsankov N. Tattoos: dermatological complications. Clin Dermatol 2007; 25: 375-382.
Kluger N. Cutaneous and systemic complications associated with tattooing. Presse Med 2016; 45: 567-576.
Kluger N, De Cuyper C. A practical guide about tattooing in patients with chronic skin disorders and other medical conditions. Am J Clin Dermatol 2018; 19: 167-180.
Kluger N, Estève E, Fouéré S et al. Tattooing and psoriasis: a case series and review of the literature. Int J Dermatol 2017; 56: 822-827.
Grodner C, Kluger N, Fougerousse AC et al. Tattooing and psoriasis: dermatologists’ knowledge, attitudes and practices. An international study. J Eur Acad Dermatol Venereol 2019; 33: e38-e40.
Kluger N. Tattooing and psoriasis: demographics, motivations and attitudes, complications, and impact on body image in a series of 90 Finnish patients. Acta Dermatovenerol Alp Pannonica Adriat 2017; 26: 29-32.
Høgsberg T, Hutton Carlsen K, Serup J. High prevalence of minor symptoms in tattoos among a young population tattooed with carbon black and organic pigments. J Eur Acad Dermatol Venereol l 2013; 27: 846-852.
Klügl I, Hiller KA, Landthaler M, Bäumler W. Incidence of health problems associated with tattooed skin: a nation-wide survey in German-speaking countries. Dermatology 2010; 221: 43-50.
Muller CS, Oertel A, Korner R et al. Socio-epidemiologic aspects and cutaneous side effects of permanent tattoos in Germany - Tattoos are not restricted to a specific social phenotype. Dermatoendocrinol 2016; 9: e1267080.
Kluger N. Cutaneous complications related to tattoos: 31 cases from Finland. Dermatology 2017; 233: 100-109.
Kluger N. Self-reported tattoo reactions in a cohort of 448 French tattooists. Int J Dermatol 2016; 55: 764-768.
Liszewski W, Kream E, Helland S et al. The demographics and rates of tattoo complications, regret, and unsafe tattooing practices: a cross-sectional study. Dermatol Surg 2015; 41: 1283-1289.
Hutton Carlsen K, Serup J. Photosensitivity and photodynamic events in black, red and blue tattoos are common: A ‘Beach Study’. J Eur Acad Dermatol Venereol 2014; 28: 231-237.
Kluger N. Tattooing and piercing: an underestimated issue for immunocompromised patients? Presse Med 2013; 42: 791-794.
Kluger N. Isotretinoin and tattooing: a cautionary tale. Int J Dermatol 2017; 56: e199-e200.
Bachmeyer C, Blum L, Petitjean B et al. Granulomatous tattoo reaction in a patient treated with etanercept. J Eur Acad Dermatol Venereol 2007; 21: 550-552.